Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809495 | 0.90 | GRM2 (0.58) | GRM2ALDH1A1TSHRHTTL3MBTL1 | |
| SCHEMBL20082374 | 0.79 | TSHR (0.51) | GRM2ALDH1A1TSHRHTTL3MBTL1 | |
| SCHEMBL503163 | 0.78 | ALDH1A1 (0.60) | GRM2ALDH1A1TSHRL3MBTL1MEN1 | |
| SCHEMBL21202394 | 0.76 | ALDH1A1 (0.48) | GRM2ALDH1A1TSHRL3MBTL1MEN1 | |
| SCHEMBL840083 | 0.76 | MEN1 (0.59) | GRM2ALDH1A1TSHRL3MBTL1MEN1 | |
| SCHEMBL10830714 | 0.75 | MEN1 (0.62) | ALDH1A1L3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11644774 | 0.73 | MEN1 (0.60) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL7679420 | 0.73 | MAPT (0.57) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL8355374 | 0.73 | GRM2 (0.50) | GRM2ALDH1A1TSHRHTTL3MBTL1 | |
| SCHEMBL14191672 | 0.73 | ALDH1A1 (0.56) | GRM2ALDH1A1TSHRHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | HTR1D, DRD2, DRD1 | GRM2 38/4885ALDH1A1 1637/4885TSHR 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.